AI Diagnostics: The End of the High-Cost Imaging Era

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

• The SAPIEN M3 system's ability to provide fully percutaneous mitral valve replacement that safely delivers near elimination of significant mitral regurgitation is a game-changer for patients

  80% confidence

• Device-as-a-Service subscription model will shorten sales cycles and build recurring revenue streams making technology accessible to more healthcare facilities without large upfront capital investments

  80% confidence

• The AI medical imaging market is entering a phase of explosive 25.8% annual growth through 2034

  80% confidence

• Partnership with Summit Sciences will enable delivery of more compelling value propositions to customers and ensure solutions make strong economic sense for healthcare providers

  80% confidence

• Aetna's coverage decision is a pivotal step in expanding access to AI-driven plaque quantification technology, with coverage now available for the majority of insured lives across the United States

  80% confidence

• Stroke patients require quick treatment access, but in-hospital stroke patients often experience hours of delay, making the Ceribell System's potential for accurate and timely LVO stroke detection critically important

  80% confidence

• Value-based care is reaching a digital tipping point in 2026 where connected platforms are no longer a 'nice-to-have' but a survival requirement for healthcare providers

  80% confidence

• 2025 marked another outstanding year for AtriCure with strong growth and transformative innovation, including new product launches, LeAAPS trial enrollment completion, and significant business leverage

  80% confidence

Cited in these Via News reports

• Medical Device Makers Deploy AI Monitoring as $1.8B Restructuring Reshapes Global Healthcare Tech →